Treatment of geographic atrophy by the topical administration of OT-551: results of a phase II clinical trial.

ABSTRACT:

Purpose

To investigate the safety and preliminary efficacy of OT-551, a disubstituted hydroxylamine with antioxidant properties, for the treatment of geographic atrophy (GA), the advanced atrophic form of age-related macular degeneration (AMD).

Methods

The study was a single-center, open-label phase II trial, enrolling 10 participants with bilateral GA. Topical 0.45% OT-551 was administered in one randomly assigned eye three times daily for 2 years. Safety measures were assessed by complete ophthalmic examination, fundus photography, and review of symptoms. The primary efficacy outcome measure was the change in best corrected visual acuity at 24 months. Secondary efficacy measures included changes in area of GA, contrast sensitivity, microperimetry measurements, and total dr

SUBMITTER: Wong WT 

PROVIDER: S-EPMC3055748 | biostudies-literature | 2010 Dec

REPOSITORIES: biostudies-literature